161 related articles for article (PubMed ID: 6261926)
1. A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy.
Chang AE; Shiling DJ; Stillman RC; Goldberg NH; Seipp CA; Barofsky I; Rosenberg SA
Cancer; 1981 Apr; 47(7):1746-51. PubMed ID: 6261926
[TBL] [Abstract][Full Text] [Related]
2. Delata-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation.
Chang AE; Shiling DJ; Stillman RC; Goldberg NH; Seipp CA; Barofsky I; Simon RM; Rosenberg SA
Ann Intern Med; 1979 Dec; 91(6):819-24. PubMed ID: 293141
[TBL] [Abstract][Full Text] [Related]
3. Antiemetic effect of delta 9-tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to placebo and compazine.
Orr LE; McKernan JF
J Clin Pharmacol; 1981; 21(S1):76S-80S. PubMed ID: 6271846
[TBL] [Abstract][Full Text] [Related]
4. Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis.
Orr LE; McKernan JF; Bloome B
Arch Intern Med; 1980 Nov; 140(11):1431-3. PubMed ID: 6254456
[TBL] [Abstract][Full Text] [Related]
5. Comparative trial of the antiemetic effects of THC and haloperidol.
Neidhart JA; Gagen MM; Wilson HE; Young DC
J Clin Pharmacol; 1981; 21(S1):38S-42S. PubMed ID: 6271838
[TBL] [Abstract][Full Text] [Related]
6. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial.
Grimison P; Mersiades A; Kirby A; Lintzeris N; Morton R; Haber P; Olver I; Walsh A; McGregor I; Cheung Y; Tognela A; Hahn C; Briscoe K; Aghmesheh M; Fox P; Abdi E; Clarke S; Della-Fiorentina S; Shannon J; Gedye C; Begbie S; Simes J; Stockler M
Ann Oncol; 2020 Nov; 31(11):1553-1560. PubMed ID: 32801017
[TBL] [Abstract][Full Text] [Related]
7. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy.
Sallan SE; Zinberg NE; Frei E
N Engl J Med; 1975 Oct; 293(16):795-7. PubMed ID: 1099449
[TBL] [Abstract][Full Text] [Related]
8. Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo.
Frytak S; Moertel CG; O'Fallon JR; Rubin J; Creagan ET; O'Connell MJ; Schutt AJ; Schwartau NW
Ann Intern Med; 1979 Dec; 91(6):825-30. PubMed ID: 517882
[TBL] [Abstract][Full Text] [Related]
9. Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting.
Citron ML; Herman TS; Vreeland F; Krasnow SH; Fossieck BE; Harwood S; Franklin R; Cohen MH
Cancer Treat Rep; 1985 Jan; 69(1):109-12. PubMed ID: 2981616
[TBL] [Abstract][Full Text] [Related]
10. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
[TBL] [Abstract][Full Text] [Related]
11. delta 9-tetrahydrocannabinol in clinical oncology.
Poster DS; Penta JS; Bruno S; Macdonald JS
JAMA; 1981 May 22-29; 245(20):2047-51. PubMed ID: 6262541
[TBL] [Abstract][Full Text] [Related]
12. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens.
Cubeddu LX; Hoffman IS; Fuenmayor NT; Finn AL
J Clin Oncol; 1990 Oct; 8(10):1721-7. PubMed ID: 2145400
[TBL] [Abstract][Full Text] [Related]
13. delta 9-Tetrahydrocannabinol for refractory vomiting induced by cancer chemotherapy.
Lucas VS; Laszlo J
JAMA; 1980 Mar; 243(12):1241-3. PubMed ID: 6244418
[TBL] [Abstract][Full Text] [Related]
14. High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer.
Bosnjak SM; Nesković-Konstantinović ZB; Radulović SS; Susnjar S; Mitrovi LB
J Chemother; 2000 Oct; 12(5):446-53. PubMed ID: 11128567
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy.
McCabe M; Smith FP; Macdonald JS; Woolley PV; Goldberg D; Schein PS
Invest New Drugs; 1988 Sep; 6(3):243-6. PubMed ID: 2847994
[TBL] [Abstract][Full Text] [Related]
16. Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol.
Ekert H; Waters KD; Jurk IH; Mobilia J; Loughnan P
Med J Aust; 1979 Dec; 2(12):657-9. PubMed ID: 231736
[TBL] [Abstract][Full Text] [Related]
17. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
Shih V; Wan HS; Chan A
Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind comparison of a prochlorperazine-based versus a metoclopramide-based antiemetic regimen in patients undergoing autologous bone marrow transplantation.
Gilbert CJ; Ohly KV; Rosner G; Peters WP
Cancer; 1995 Dec; 76(11):2330-7. PubMed ID: 8635039
[TBL] [Abstract][Full Text] [Related]
19. Nabilone: an effective antiemetic in patients receiving cancer chemotherapy.
Einhorn LH; Nagy C; Furnas B; Williams SD
J Clin Pharmacol; 1981; 21(S1):64S-69S. PubMed ID: 6271844
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy.
Fraschini G; Ciociola A; Esparza L; Templeton D; Holmes FA; Walters RS; Hortobagyi GN
J Clin Oncol; 1991 Jul; 9(7):1268-74. PubMed ID: 1828499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
